8-K: Organon & Co. Reports Solid First Quarter 2024 Results, Revenue Up 7% at Constant Currency

Organon & Co. announced a 7% revenue increase at constant currency for the first quarter of 2024, driven by growth in Women's Health and Biosimilars.

Summary

• Organon & Co. reported first quarter 2024 revenue of $1,622 million, a 5% increase on an as-reported basis and a 7% increase at constant currency compared to the same period last year.
• The company's Women's Health revenue grew by 11% as reported and 12% at constant currency, primarily driven by a 34% increase in Nexplanon sales.
• Biosimilars revenue saw a significant increase of 46% both on an as-reported and constant currency basis, boosted by Ontruzant sales.
• Established Brands revenue was flat on an as-reported basis but grew 2% at constant currency.
• Diluted earnings per share (EPS) were $0.78, while non-GAAP adjusted diluted EPS reached $1.22, both including a $0.05 per share impact from acquired in-process research and development (IPR&D) and milestones.
• Net income for the quarter was $201 million, and adjusted EBITDA was $538 million.
• The company affirmed its full-year 2024 financial guidance ranges.

Sentiment

Score: 7

Explanation: The sentiment is positive due to solid revenue growth, particularly in Women's Health and Biosimilars, and the reaffirmation of full-year guidance. However, there are some concerns about margin compression and generic competition.

Positives

• The company experienced strong revenue growth in Women's Health and Biosimilars.
• Nexplanon sales saw a significant increase of 34% at constant currency.
• Biosimilars revenue grew by 46% at constant currency.
• The company's adjusted diluted EPS increased to $1.22.
• Organon affirmed its full-year 2024 financial guidance ranges.
• The Jada system sales nearly doubled compared to the prior year period.
• Hadlima is continuing to gain traction in the U.S. market.

Negatives

• NuvaRing sales declined by 19% at constant currency due to generic competition.
• The fertility portfolio was down 2% ex-FX.
• Gross margin decreased to 59.0% as-reported and 62.1% on a non-GAAP adjusted basis.
• Adjusted EBITDA margin decreased to 33.2% from 33.7% in the prior year period.
• Other revenue decreased by 29% at constant currency.

Risks

• The company faces risks related to pricing pressures, including managed care and government regulations.
• There are risks associated with executing product development and commercialization plans.
• The company is exposed to changes in tax laws and potential audit scrutiny.
• There is competition from generic products as patents expire.
• The company faces challenges in obtaining additional market exclusivity for Nexplanon after 2027.
• The company is exposed to political and social pressures that could impact demand for contraception and fertility products.
• The company is exposed to general economic factors, including recessionary pressures, interest rate and currency exchange rate fluctuations.

Future Outlook

The company reaffirmed its full-year 2024 financial guidance, expecting revenue between $6.2 billion and $6.5 billion and maintaining adjusted EBITDA margins between 31.0% and 33.0%. The company expects flat performance in Established Brands for the full year 2024 on an ex-FX basis.

Management Comments

• Kevin Ali, Organon's Chief Executive Officer, stated that the first quarter was a very solid start to the year.
• He also expressed confidence in the company's ability to deliver its third year of revenue growth on a constant currency basis.
• Management remains committed to delivering full-year non-GAAP Adjusted EBITDA margins that are in line with last year, or better.

Industry Context

Organon's performance reflects the ongoing trends in the pharmaceutical industry, including the growth of biosimilars and the challenges of generic competition impacting established brands. The company's focus on women's health aligns with a growing global emphasis on this sector.

Comparison to Industry Standards

• Organon's 7% constant currency revenue growth is a solid performance compared to some of its peers in the pharmaceutical sector, although specific comparisons are difficult without detailed competitor data.
• The 46% growth in biosimilars revenue is particularly strong, indicating a successful strategy in this area, which is a key growth driver for many pharmaceutical companies.
• The decline in NuvaRing sales due to generic competition is a common challenge faced by companies with established brands, similar to what companies like Teva and Mylan have experienced.
• The company's adjusted EBITDA margin of 33.2% is within the range of other pharmaceutical companies, but specific comparisons would require a more detailed analysis of peer group performance.

Stakeholder Impact

• Shareholders will benefit from the declared quarterly dividend of $0.28 per share.
• Employees are likely to be impacted by the company's cost containment initiatives.
• Customers will continue to have access to Organon's products.
• Suppliers may be impacted by the company's efforts to manage costs.

Next Steps

• The company will continue to focus on delivering its 2024 financial targets.
• Organon will host a conference call to discuss the first quarter results.
• The company will continue to invest in innovation and future growth opportunities in women's health and biosimilars.

Key Dates

Keywords

Organon, Women's Health, Biosimilars, Established Brands, Revenue, Earnings Per Share, EBITDA, Nexplanon, Ontruzant, Hadlima, Financial Results, Pharmaceuticals